KOLINPHARMA^® achieved the first patent in China for Doltendix®. The total number of patents obtained thus rises to n. 49, further strengthening our intellectual property and consolidating our position on the international market. The patent in China represents strategical and competitive strengths, which allowed us to defend and value a product still with still successfully marketed in this dynamical market.

DOLTENDIX^® is a food supplement based on bioactive peptides from collagen, astaxanthin, trans-resveratrol and vitamin C, formulated for the well-being of the tendons. It is the result of an innovative formulation that demonstrates KOLINPHARMA’s ongoing commitment to research and develop cutting-edge solutions aimed at the well-being of consumers.

We are proud to continue Italian excellence in the nutraceutical sector and to contribute to improving people’s well-being.